These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30887675)

  • 21. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
    Montgomery RA; Orandi BJ; Racusen L; Jackson AM; Garonzik-Wang JM; Shah T; Woodle ES; Sommerer C; Fitts D; Rockich K; Zhang P; Uknis ME
    Am J Transplant; 2016 Dec; 16(12):3468-3478. PubMed ID: 27184779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
    Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
    Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
    Rostaing L; Maggioni S; Hecht C; Hermelin M; Faudel E; Kamar N; Sallusto F; Doumerc N; Allal A
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():165-9. PubMed ID: 25894148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
    Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
    Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
    Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
    Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 37-year kidney transplantation experience at Siriraj Hospital.
    Premasathian N; Vongwiwatana A; Taweemonkongsap T; Amornvesukit T; Limsrichamrern S; Jitpraphai S; Kositamongkol P; Mahawithitwong P; Sritippayawan S; Chanchairujira T; Nualyong C; Vareesangthip K; Vasuvattakul S; Sirivatanauksorn Y
    Clin Transpl; 2010; ():141-8. PubMed ID: 21696037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases.
    Yabu JM; Pando MJ; Busque S; Melcher ML
    Transplant Proc; 2013; 45(1):82-7. PubMed ID: 23375278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Ruiz P; Vianna R; Burke GW
    Clin Transplant; 2018 Oct; 32(10):e13392. PubMed ID: 30152116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody-Mediated Rejection.
    Halleck F; Böhmig GA; Couzi L; Rostaing L; Einecke G; Lefaucheur C; Legendre C; Montgomery R; Hughes P; Chandraker A; Wyburn K; Halloran P; Maldonado AQ; Sjöholm K; Runström A; Lefèvre P; Tollemar J; Jordan S
    Clin Transplant; 2024 Jul; 38(7):e15383. PubMed ID: 39023092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients.
    Patel JK; Coutance G; Loupy A; Dilibero D; Hamilton M; Kittleson M; Kransdorf E; Azarbal B; Seguchi O; Zhang X; Chang D; Geft D; Czer L; Varnous S; Kobashigawa JA
    Am J Transplant; 2021 Jul; 21(7):2479-2488. PubMed ID: 33251691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in desensitization of crossmatch-positive kidney transplant recipients.
    Morath C; Opelz G; Zeier M; Süsal C
    Transplant Proc; 2012; 44(6):1648-51. PubMed ID: 22841236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.